ClinicalTrials.gg
CompletedNCT07951541PH1070Updated Nov 20, 2026

Pilot Study on the Effects of Snap Supplements Prostate Health Formula on Urinary Symptoms in Men Over 50

An observational study in Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS) and Urinary Frequency, sponsored by Snap Supplements. Completed at 1 site in United States. Open to male participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Snap Supplements · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Enrollment
25th of 37
50 · median 201
Started
2025
with 8 others
Observational
37 of 188
12 open now
Registered
188th of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 25th largest by enrollment of the 37 observational ones that give a count, is one of 9 that started in 2025, is one of 37 observational ones, and was the 188th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

This is a decentralized, observational pilot study evaluating the potential effects of Snap Supplements Prostate Health on urinary symptoms in men aged 50 years and older. Prostate enlargement and related urinary issues, such as daytime frequency, nighttime urination (nocturia), and urgency, are common with age and may negatively affect quality of life and sleep.

In this study, approximately 50 participants will take three capsules of Snap Supplements Prostate Health nightly for 90 days while completing brief daily surveys using a secure online platform (Alethios). Surveys will track urinary frequency, nocturia, urgency, and sleep quality, with additional questions about product tolerability, satisfaction, and overall experience.

The main goal is to explore whether taking the supplement for 90 days is associated with improvement in urinary symptoms compared with each participant's own baseline. This is a single-group, pre-post study without randomization or placebo. No in-person visits are required; all activities occur at home.

The supplement contains a blend of natural ingredients (such as saw palmetto, beta-sitosterol, nettle root, turmeric, green tea extract, and mushroom extracts) that have been studied for their potential effects on prostate and urinary health. The study will help characterize user experiences in a real-world setting and generate preliminary data to inform future research.

Participation is voluntary, and participants may withdraw at any time. Compensation is provided for completing surveys. Risks are expected to be minimal, with possible mild gastrointestinal or allergic-type reactions.

Read the detailed description

Study Overview

This is a decentralized, open-label, single-group, pre-post observational pilot study designed to evaluate the association between daily use of Snap Supplements Prostate Health and changes in urinary symptoms in men aged 50 years and older. The study will recruit and follow approximately 50 participants over a 90-day period.

All study activities are conducted remotely through the Alethios digital research platform, which supports electronic informed consent, daily survey reporting, interim/final assessments, and adverse event reporting. No in-person visits or clinical procedures are required.

Background and Rationale

Age-related prostate enlargement (benign prostatic hyperplasia, BPH) is highly prevalent among men over 50 and often associated with lower urinary tract symptoms (LUTS), including daytime frequency, nocturia, and urgency. These symptoms can disrupt sleep and quality of life. While medications exist, some men seek alternative or adjunctive options with fewer side effects.

Snap Supplements Prostate Health is a commercially available dietary supplement containing plant sterols (beta-sitosterol), saw palmetto, nettle root, turmeric (curcumin), reishi and maitake mushroom extracts, and green tea extract. Prior clinical and mechanistic studies suggest these ingredients may support urinary comfort, reduce symptom burden, and promote prostate health. This study aims to evaluate user-reported changes in urinary symptoms during 90 days of nightly supplement use in a real-world, at-home setting.

Objectives

Primary Aim:

To assess whether 90 days of Snap Supplements Prostate Health is associated with improvements in:

Daytime urinary frequency

Nocturia (nighttime urination)

Urinary urgency

Secondary Aims:

Evaluate self-reported sleep quality at baseline, Day 30, Day 60, and Day 90

Collect consumer perceptions regarding symptom relief, satisfaction, daily-life impact, tolerability, and willingness to continue use

Study Design

Type: Single-group, pre-post, observational study

Intervention: 3 capsules of Snap Supplements Prostate Health nightly for 90 consecutive days

Duration: 90 days per participant

Sample size: \~50 men aged 50 years and older

Study site: Fully decentralized, via the Alethios online platform

Eligibility Criteria

Inclusion:

Male, age ≥50

Self-reported urinary symptoms (frequency, nocturia, urgency)

Willing and able to complete daily online surveys for 90 days

Not currently taking other prostate-related supplements or medications (or willing to discontinue)

Exclusion:

History of prostate cancer or urologic disorder requiring treatment

Significant chronic illness affecting urinary function (e.g., uncontrolled diabetes, neurologic conditions)

Known allergies to supplement ingredients (turmeric, nettle root, saw palmetto, mushrooms, green tea)

Current use of medications that interact with curcumin (selected chemotherapy, anticoagulants, immunosuppressants)

Data Collection and Assessments

Baseline: Demographics, medical/supplement history, symptom severity

Daily Surveys: Daytime urinary frequency, nocturia, urgency rating (1-10)

Interim Surveys (Days 30 \& 60): Sleep quality, symptom check

Final Survey (Day 90): Sleep quality, symptom check, consumer perception outcomes (satisfaction, tolerability, daily impact, willingness to continue)

Estimated participant burden: \~1-2 minutes/day for surveys; 5-10 minutes each for interim/final assessments.

Outcomes

Primary Outcomes:

Within-participant change from baseline to Day 90 in urinary frequency (day and night) and urgency

Secondary Outcomes:

Within-participant change in self-reported sleep quality (baseline vs. Day 30, 60, 90)

Descriptive measures of consumer perceptions, tolerability, and satisfaction

Statistical Analysis

Primary analyses: Pre-post comparisons using paired t-tests or Wilcoxon signed-rank tests, as appropriate

Longitudinal analyses: Mixed-effects models with random intercepts to estimate change over time in frequency counts, urgency, and sleep quality

Secondary outcomes: Descriptive summaries and exploratory models for perception and tolerability endpoints

Risks and Benefits

Risks are minimal and primarily include mild gastrointestinal upset, allergic-type reactions, or rare sensitivity to ingredients (e.g., green tea extract, turmeric). Participants are instructed to take capsules with food to minimize risk. Adverse events can be reported 24/7 via the study platform and will be reviewed promptly.

Direct health benefits are not guaranteed. Participants may gain insight into symptom patterns over time. The main benefit is contributing to research on natural approaches to prostate and urinary health.

Confidentiality

Data will be collected and stored via the HIPAA- and 21 CFR Part 11-compliant Alethios platform. Information is de-identified, encrypted, and stored securely. Personally identifiable information (PII) is separated from study data and accessible only to authorized staff.

Compensation

Participants who complete ≥75% of study surveys will receive a $20 Amazon gift card. There are no costs to participants.

Study Timeline

IRB Submission: Within 2 weeks of protocol finalization

Enrollment: \~2-3 weeks post-IRB approval

Data Collection: 90 days per participant

Analysis \& Report: Within 3 months after study completion

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)
  • Lower Urinary Tract Symptoms (LUTS)
  • Urinary Frequency
  • Nocturia
  • Prostate Health

Keywords

  • Prostate Supplement
  • Herbal Supplement
  • Men's Health
  • Sleep Quality
  • Dietary Supplement
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Men aged 50 and older with self-reported urinary symptoms consistent with age-related prostate enlargement. Participants must be capable of completing daily online surveys over a 90-day period. Recruitment will occur remotely through online advertising and email outreach, with enrollment and all data collection conducted via the Alethios digital platform.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male, age ≥50 years

Self-reported prostate-related urinary symptoms (daytime frequency, nocturia, urgency)

Able and willing to complete daily surveys for 90 days

Not currently taking prostate-related supplements or medications (or willing to discontinue prior to study)

Exclusion criteria

Exclusion Criteria:

  • History of prostate cancer or urologic disorders requiring active treatment

Significant chronic illness affecting urinary function (e.g., uncontrolled diabetes, neurologic conditions)

Known allergy to any study product ingredients (turmeric, nettle root, saw palmetto, green tea, maitake or reishi mushrooms)

Current use of medications likely to influence urinary patterns (e.g., diuretics, alpha-blockers) unless stabilized and documented

Current use of medications known to interact with curcumin (e.g., certain chemotherapies, warfarin/anticoagulants, such as tacrolimus)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (actual)
Patient registry
No

Interventions

  • Dietary supplementProstate Health Supplement

    Participants will take three capsules nightly of a commercially available dietary supplement, Prostate Health (Snap Supplements), for 90 consecutive days. The formulation contains a blend of plant-derived and botanical ingredients that have been studied for potential effects on prostate and urinary health. Key components include: beta-sitosterol and other phytosterols, saw palmetto extract, stinging nettle root extract, turmeric (curcumin), green tea extract (EGCG), reishi mushroom, and maitake mushroom. Participants will self-administer the product at home with water, preferably with food, and record daily urinary symptoms using a secure digital platform. No placebo or comparator is included.

06

What researchers measure

Primary outcomes

  1. Change in Daytime Urinary Frequency

    Number of daytime urinations per 24 hours, self-reported daily using the Alethios survey platform. Change from baseline to Day 90 will be assessed within participants.

    Time frame: Baseline to Day 90

  2. Change in Nighttime Urinary Frequency (Nocturia)

    Number of times participants wake at night to urinate, self-reported daily. Change from baseline to Day 90 will be assessed within participants.

    Time frame: From Baseline to Day 90

  3. Change in Urinary Urgency

    Participant-rated urinary urgency on a 1-10 numeric rating scale (higher = greater urgency), reported daily. Change from baseline to Day 90 will be assessed.

    Time frame: Baseline to Day 90

07

Study locations

1 site
  • Decentralized Study
    San Francisco, California 94104, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Feb 2026, 4 months.

Of 74 observational studies under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Oct 20, 2025
Primary completionActual
Feb 27, 2026
CompletionActual
Feb 27, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951541
Lead sponsor
Snap Supplements
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Oct 20, 2025
Primary completion
Feb 27, 2026
Completion
Feb 27, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion